Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triaminic is a brand of over-the-counter (OTC) combination medications primarily used to treat symptoms associated with the common cold, influenza, and respiratory allergies. The product line includes various formulations tailored for pediatric and adult use, typically containing a combination of active ingredients such as antihistamines (e.g., chlorpheniramine, diphenhydramine), nasal decongestants (e.g., phenylephrine, pseudoephedrine), cough suppressants (e.g., dextromethorphan), and analgesics/antipyretics (e.g., acetaminophen). These components work through distinct mechanisms: antihistamines antagonize H1 receptors to reduce allergic responses; decongestants act as alpha-adrenergic agonists to constrict nasal blood vessels; cough suppressants act on the medullary cough center; and analgesics inhibit prostaglandin synthesis. Originally marketed by Novartis, the brand is currently distributed by GSK Consumer Healthcare.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Triaminic.